Quick Read
- New Line Cinema has officially confirmed Lori Evans Taylor as the screenwriter for Final Destination 7.
- The project follows the massive commercial success of 2025’s Bloodlines, which grossed $317.9 million worldwide.
- Studio executives are currently in final negotiations with director Michiel Blanchart for a projected Summer 2027 release.
New Line Cinema has officially transitioned Final Destination 7 from speculative development to an active priority, confirming that screenwriter Lori Evans Taylor has been tapped to pen the screenplay. The announcement marks a significant milestone for the horror franchise, which saw a major resurgence following the critical and commercial performance of its 2025 predecessor.
Building on the Success of Bloodlines
The decision to bring back Taylor, who co-wrote Final Destination: Bloodlines, signals a strategy of creative continuity. Bloodlines shattered previous franchise records, grossing $317.9 million at the global box office and earning a 92% approval rating on Rotten Tomatoes. By securing the same creative voice for the seventh installment, studio executives are aiming to replicate the blend of franchise-staple death sequences and character-driven narrative depth that resonated with modern audiences.
The Future of the Final Destination Franchise
The franchise has generated over $1 billion in total global revenue, cementing its status as a cornerstone of horror cinema. Industry reports indicate that Michiel Blanchart, the director behind Night Call, is currently in final negotiations to helm the project. If finalized, the production will look to maintain the momentum established by the 2025 release, with a theatrical window currently eyed for Summer 2027.
Strategic Shifts in Horror Reboots
The rapid mobilization of Final Destination 7 reflects a broader industry trend where studios are leveraging established horror intellectual property to drive box office stability. Much like the recent Scream reboots, the studio appears to be banking on the audience’s appetite for familiar, high-stakes horror concepts that are updated with fresh creative direction. This approach mitigates the risk of total failure while capitalizing on the built-in, multi-generational fan base that has sustained the series for over two decades.
The successful pivot of the Final Destination franchise demonstrates that legacy horror IPs remain a highly viable asset in the current theatrical market, provided that studios prioritize creative consistency and narrative evolution over mere brand recognition.